Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

DREAM

Objective

The EvergreenHealth Multiple Sclerosis Center is conducting a randomized, double-blind, placebo-controlled, cross-over trial to assess the safety, tolerability, and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue.

Who may be eligible to participate?

Patients 18-75 years of age with a confirmed diagnosis of Multiple Sclerosis and Insomnia Disorder. Patients must be on a stable regimen of disease modifying therapy with no MS exacerbations for 60 days prior to screening.

What does participation involve?

This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS. Enrolled patients will come to the study site for 4 visits (45-90 minutes each) during the study. Patients will also have 3 or more phone conversations with a study coordinator.

Investigator

Theodore Brown, MD, MPH, EvergreenHealth MS Center

Clinical Trial Categories

  • Multiple Sclerosis
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com